Medical Condition News

RSS

Researchers devise strategy to directly activate natural ‘death’ protein

Researchers at Dana-Farber/Children's Hospital Cancer Center have devised a strategy to directly activate a natural "death" protein, triggering the self-destruction of cells. They say the development could represent a new paradigm for designing cancer drugs.

1 Jun 2012

Researchers investigate how iPFK2 enzyme may benefit some obese people

Why is it that some obese people are healthier than others? This was one of the main questions Dr. Chaodong Wu of the College of Agriculture and Life Sciences - Texas A&M University System - and a group of researchers tried to answer in a recent study.

1 Jun 2012

IU scientists successfully transplant primary kidney cells intravenously to treat renal failure

Indiana University School of Medicine scientists have successfully transplanted primary kidney cells intravenously to treat renal failure in rats, pointing the way to a possible future alternative to kidney transplants and expensive dialysis treatments in humans.

1 Jun 2012

Clove oil could cause an allergic skin reaction

McCord Research the parent company of Pinnaclife warns consumers that fruit that is protected from infestation or bacteria by an ingredient as common as clove oil could cause an allergic skin reaction.

1 Jun 2012

NCI, Tau Therapeutics open enrollment in mibefradil Phase Ib glioma trial

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.

1 Jun 2012

Oncothyreon commences PX-866 and vemurafenib Phase 1/2 combination trial for melanoma

Oncothyreon Inc. today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib.

1 Jun 2012

RXi’s RXI-109 IND receives FDA clearance to proceed into clinical trials

RXi Pharmaceuticals Corporation today announced that it has received clearance for its investigational new drug application (IND) from the U.S. Food and Drug Administration (FDA) to initiate clinical trials with RXI-109, a self-delivering RNAi compound that selectively targets Connective Tissue Growth Factor.

1 Jun 2012

Aspirin controls two key processes to kill bowel cancer cells

Aspirin kills cancer cells by controlling two key processes that influence energy use in cells and could explain how aspirin can prevent bowel cancer. The research is published in this month's Gastroenterology.

1 Jun 2012

IL-6 protein plays a pivotal role in the duration of acute pancreatitis

Scientists from the Universities of Illinois and California have found that the inflammatory protein interleukin-6 (IL-6) plays a pivotal role in the duration of acute pancreatitis in animal models with this condition.

1 Jun 2012

suPAR protein can serve as marker for blood poisoning

Blood poisoning is a serious problem in medical care. Research from Malmö University in Sweden now shows that the protein suPAR, which can be used for early detection of critical cases of sepsis, is found in saliva, which opens new potential for tracking diseases.

1 Jun 2012

FDA approves RBI’s AppliGel-G for human testing

Royer Biomedical, Inc. (RBI) received FDA approval to proceed with Human Testing of AppliGel-G (Gentamicin) in management of Diabetic Foot Ulcers.

1 Jun 2012

Smoker's genetic makeup can help predict response to drug therapy

The same gene variations that make it difficult to stop smoking also increase the likelihood that heavy smokers will respond to nicotine-replacement therapy and drugs that thwart cravings, a new study shows.

31 May 2012

Counseling sessions with community pharmacist lead to better medication adherence

A new Walgreens study has found that patients starting high cholesterol (statin) medication for the first time who participated in enhanced face-to-face counseling sessions with a community pharmacist demonstrated better medication adherence than those that did not participate in the sessions.

31 May 2012

New therapy approach for patients blind on one side

Patients who are blind in one side of their visual field benefit from presentation of sounds on the affected side. After passively hearing sounds for an hour, their visual detection of light stimuli in the blind half of their visual field improved significantly.

31 May 2012

Too much salt and aldosterone leads to high blood pressure, tissue damage

Nearly 40 percent of the small adrenal tumors that cause big problems with high blood pressure share a genetic mutation that causes patients to retain too much sodium, researchers report.

31 May 2012

New method can solve 3-D structures of integral membrane proteins

A new method for rapidly solving the three-dimensional structures of a special group of proteins, known as integral membrane proteins, may speed drug discovery by providing scientists with precise targets for new therapies, according to a paper published May 20 in Nature Methods.

31 May 2012

Juvenile Arthritis patients may have difficulties achieving educational success

As children with juvenile idiopathic arthritis (JIA) grow into adulthood, disability due to disease may adversely affect their ability to achieve educational success. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), suggest that functional disability impacts educational attainment, which is key to successful employment in adulthood.

31 May 2012

Researchers identify new peptide that can block fibrosis of the skin and lungs

A member of the Scleroderma Foundation's Board of Directors has led a team of researchers who have identified a peptide that can block fibrosis of the skin and lungs, according to a report published today.

31 May 2012

Risk of gout flare-ups greatly increased by purine rich foods

Foods rich in purines, particularly those found in meat and seafood, quintuple the immediate risk of a gout flare-up, finds research published online in the Annals of the Rheumatic Diseases.

31 May 2012

Mayo Clinic offers new technology for treatment of dry eye

Mayo Clinic in Arizona is the first medical center in Arizona and the Southwest to provide a new technology that treats dry eye by targeting blocked eyelid glands. Blocked glands can inhibit production of oil that is necessary for healthy tears needed to lubricate the eyes.

31 May 2012